Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 15 December 2014 | By Alexander Gaffney, RAC,
New legislation set to be signed into law by US President Barack Obama would ban dozens of active ingredients now used in the production of anabolic steroids, and also make it easier for federal authorities to prohibit the production of similar products.
The legislation, the Designer Anabolic Steroid Control Act (DASCA)of 2014, was passed by the US House of Representatives on 15 September 2014, and the US Senate on 11 December 2014.
According to its sponsors, the bill is intended to prevent steroid products from being marketed as nutritional supplements or being distributed using false labeling.
"Designer steroids are produced by reverse engineering existing illegal steroids and then slightly modifying their chemical composition, so the resulting product is not on the Drug Enforcement Administration’s (DEA) list of controlled substances," Sen. Orrin Hatch, one of the bill's sponsors, explained in a statement.
The bill takes two approaches to banning designer steroids.
First, it bans 25 designer steroid ingredients already known to federal regulators from being sold over the counter by adding them to the Controlled Substances Act (CSA) as Schedule III drugs.
Second, the bill allows other drug ingredients that are in "chemical structure substantially similar to one or more anabolic steroids" added to the CSA by the DASCA to also be regulated as anabolic steroids.
Third, and perhaps most importantly, the bill creates a new "temporary" scheduling process by which the DEA can issue a "temporary order adding a drug or other substance to the definition of anabolic steroids" if it believes it to be an anabolic steroid. The temporary order would take place 30 days after the order was issued, and would expire in 24 months.
Notably, the orders "are not subject to judicial review," the law states.
The DEA may also pursue permanent rulemaking to add the drug substances to the CSA, the bill states.
Finally, the bill also increases penalties for importing, exporting, manufacturing, distributing, or dispensing anabolic steroids unless the product is clearly identified as an anabolic steroid or is approved by the US Food and Drug Administration (FDA). Violators may be fined up to $500,000 per violation.
The legislation now awaits Obama's signature.
Designer Anabolic Steroid Control Act (DASCA)
Tags: Legislation, Bill, Congress, Anabolic Steroid, Designer Anabolic Steroid Control Act, (DASCA), DEA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.